Document:

Exhibit 10.11

  

The Johns Hopkins University

School of Medicine, Duke

University

&

Second Sight, LLC

 

Exclusive License Agreement

October 24, 2000

 

    	 

    	 

    

  

EXCLUSIVE LICENSE AGREEMENT

 

This Agreement is between
The Johns Hopkins University, a corporation of the State of Maryland, having its principal place of business at 111 Market
Place, Suite 906, Baltimore, Maryland 21202, (hereinafter referred to as "JHU''); Duke University, located at 230 North
Building, Box 9008J, Durham, North Carolina 27710, (hereinafter referred to as "DUKE"); (JHU and DUKE shall
collectively be referred to as the "LICENSORS"); and Second Sight, LLC, a limited liability company of the State of
Delaware, having its principal place of business at 28460 Avenue Stanford, #200, Valencia, California 91355 (hereinafter
referred to as "SECOND SIGHT").

 

WITNESSETH:

 

WHEREAS, DUKE is the owner of certain
PATENT RIGHTS (as defined below) relating to U.S. Patent No. 5,109,844, issued on May 5, 1992, entitled "Retinal
Microstimulation" (DUKE Ref.: 594), by Eugene de Juan, Jr., Mark S. Humayun, and Howard Phillips; and JHU is
the owner of certain PATENT RIGHTS relating to "Radio Frequency Powered
Intraocular Visual Prosthesis" (JHU Ref.: DM-3153), by Mark S. Humayun, Eugene de Juan, Jr., and Robert J.
Greenberg; and "A Method for Preferential Outer Retinal Stimulation" (JHU Ref.: DM-3344), by Robert J.
Greenberg, Eugene de Juan, Jr., and Mark S. Humayun;

 

WHEREAS, as centers for research
and education, JHU and DUKE are interested in licensing PATENT RIGHTS in a manner that will benefit the public by facilitating
the distribution of useful products and the utilization of new methods, but is without capacity to commercially develop, manufacture,
and distribute any such products or methods;

  

WHEREAS, SECOND SIGHT desires to commercially
develop, manufacture, use and distribute such products and processes throughout the world; and 

 

    	1

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

NOW, THEREFORE, in consideration of
the foregoing premises and the following mutual covenants, and other good and valuable consideration, the receipt of which is
hereby -acknowledged, and intending to be legally bound hereby, the parties agree as follows:

 

ARTICLE 1-DEFINITIONS

 

1.1                "EXCLUSIVE LICENSE"
shall mean the grant by LICENSORS of their entire right and interest in PATENT RIGHTS, subject to rights retained by the United
States government in accordance with P.L. 96-517, as amended by P.L. 98-620, and as set forth in 37 CFR Part 401, and subject to
the retained right of the LICENSORS to make, have made, use and provide LICENSED PRODUCTS for their and their affiliated health
system's nonprofit clinical and internal research and educational purposes, but not to sell, distribute or otherwise make commercially
available.

 

1.2          
"PATENT RIGHTS" shall mean U.S. Patent No. 5,109,844 issued on May 5, 1992 and assigned to DUKE entitled, "Retinal
Microstimulation", and the invention disclosed and claimed therein, and any reissues based thereon and all continuations,
divisions and reissues thereof, and any corresponding foreign patent applications, and any patents, patents of addition, or other
equivalent foreign patent rights, issued, granted or registered thereon, (hereinafter "DUKE PATENT RIGHTS"); and U.S.
Patent No. 5,935,155 issued on August 10, 1999, and assigned to JHU entitled, "Radio Frequency Powered Intraocular Visual
Prosthesis", and U.S. Patent No. 5,944,747 issued on August 31, 1999, and assigned to JHU
entitled, "A Method for Preferential Outer Retinal Stimulation", and the inventions disclosed and claimed
therein, and all continuations, divisions, and reissues based thereof, and any corresponding foreign patent applications, and
any patents, patents of addition, or other equivalent foreign patent rights issuing, granted or registered thereon, (hereinafter
"JHU PATENT RIGHTS"); and any patent applications and
patents for IMPROVEMENTS (defined below) listed in Appendix A.

 

    	2

    	 

    

 

	Second  Sight, LLC
	License Agreement
	 

 

1.3
           "LICENSED PRODUCTS" shall mean any product, the
manufacture, use or sale of which would constitute, but for the license granted to SECOND SIGHT pursuant to this Agreement,
an infringement of a claim of PATENT RIGHTS (infringement shall include, but is not limited to, direct, contributory, or
inducement to infringe).

 

1.4
           "NET SALES", subject to Paragraph 3.8 below, shall
mean gross sales revenues and fees received by SECOND SIGHT, AFFILIATED COMPANIES, and SUBLICENSEES from the use, sale, or
lease of LICENSED PRODUCTS less reasonable trade discounts allowed, broker and agent fees actually paid, refunds, returns and
recalls, taxes (U.S. sales tax, foreign taxes incident to sale, but excluding income taxes) and reasonable freight and
transportation charges. In the event that the product sold is a system comprising a combination of one or more
LICENSED PRODUCTS and other components, NET SALES of any such system shall be multiplied by the fraction A/B, where
'A' is the fully burdened standard manufacturing cost of the LICENSED PRODUCTS, and 'B' is the fully burdened manufacturing
cost of the entire system. NET SALES shall exclude sales of LICENSED PRODUCTS by SECOND SIGHT, AFFILIATED COMPANIES and
SUBLICENSEES to the U.S. Government when (i) the U.S. Government has a license to PATENT RIGHTS as set forth in P.L.
96-517, as amended by P.L. 98-620, and (ii) when the U.S. Government requests that LICENSED PRODUCTS be sold at a discounted
price such that the discount is not less than the royalty rate set forth in Paragraph 3.4.

  

1.5           
"AFFILIATED COMPANY" or "AFFILIATED COMPANIES" shall mean any corporation, company, partnership, joint
venture or other entity that controls, is controlled by, or is under common control with SECOND SIGHT. For purposes of this
Paragraph 1.5, control shall mean the direct or indirect ownership of at least fifty percent (50%).

 

1.6            "SUBLICENSEE(S)"
of this License Agreement shall mean any company which is not an AFFILIATED COMPANY which is licensed by SECOND SIGHT to make,
use, sell or lease LICENSED PRODUCTS. SUBLICENSEE(S) shall not include companies to whom SECOND SIGHT sells LICENSED PRODUCTS,
(i) at fair market value, (ii) in an arms length transaction, and (iii) for the purpose of resale, use or consumption.

 

    	3

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

1.7       
    "EFFECTIVE DATE" of this Agreement shall mean the date that the last party hereto has executed
this Agreement.

 

1.8         
  "FIELD" shall mean a visual prosthesis which stimulates viable neural tissue in the visual system of blind
patients thereby producing the perception of a pixilated image.

 

1.10     
   "IMPROVEMENTS" shall mean inventions in the FIELD that are (i) made as a direct result of research
funded by SECOND SIGHT in accordance with a sponsored research agreement entered into concurrently with execution of this
Agreement; or (ii) made as a direct result of a documented collaboration between SECOND SIGHT and JHU in the laboratory of
Drs. Eugene de Juan or Mark Humayun, provided that such inventions resulting from the collaboration are not encumbered by a
third party. All IMPROVEMENTS shall be documented as being licensed hereunder by amending this Agreement to list such
IMPROVEMENTS in Appendix A.

 

ARTICLE 2- LICENSE GRANT

 

2.1      
    Subject to the terms and conditions of this Agreement, DUKE hereby grants to SECOND SIGHT an
EXCLUSIVE LICENSE to make, use, sell, and lease LICENSED PRODUCTS in the U.S. and worldwide under DUKE PATENT RIGHTS. JHU
hereby grants to SECOND SIGHT an EXCLUSIVE LICENSE to make, use, sell, and lease LICENSED PRODUCTS in the U.S. and worldwide
under JHU PATENT RIGHTS.

 

    	4

    	 

    

 

	Second  Sight, LLC
	License Agreement
	 

 

2.2      
     SECOND SIGHT is granted the right to sublicense third parties the rights, privileges, and
licenses granted hereunder. Upon any termination of this Agreement, AFFILIATED COMPANIES' and SUBLICENSEES' rights shall also
terminate, subject to the right to complete and sell all work in progress and inventory on hand. SECOND SIGHT shall forward
to LICENSORS a copy of any and all sublicense agreements promptly upon execution by the parties. SECOND SIGHT agrees that it
will only sell LICENSED PRODUCTS to its SUBLICENSEES for the purposes of re-sale; sales to a SUBLICENSEE for any other
purpose shall be prohibited without the prior written consent of JHU.

 

2.3           SECOND
SIGHT shall have the right to extend the rights granted under Paragraph 2.1 to its AFFILIATED COMPANIES; however,
such AFFILIATED COMPANIES must agree in writing to be bound
by the terms of this Agreement. A copy of any such agreement shall be promptly sent to LICENSORS. SECOND SIGHT agrees that it
will only sell LICENSED PRODUCTS to its AFFILIATED COMPANIES for the purposes of re-sale; sales to AFFILIATED COMPANIES for
any other purpose shall be prohibited without the prior written consent of JHU.

 

ARTICLE 3- PAYMENTS, ROYALTIES, AND TERMINATION

 

3.1          SECOND
SIGHT will reimburse LICENSORS for the reasonable costs of preparing, filing, maintaining and prosecuting PATENT RIGHTS
whether such costs were incurred before or after the EFFECTIVE DATE.- The total costs incurred by LICENSORS as of the
EFFECTIVE DATE are Thirty Two Thousand Six Hundred Fifty Six dollars and Ninety-five cents ($32,656.95). SECOND SIGHT shall
submit a check to JHU for such amount within thirty (30) days of the EFFECTIVE DATE of this Agreement. JHU shall be
responsible for DUKE's share of such amount Furthermore, for future patent expenses reasonably incurred by LICENSORS for
patents and patent applications in jurisdictions approved in advance by SECOND SIGHT, SECOND SIGHT shall reimburse LICENSORS
for such future expenses within thirty (30) days of receipt of invoice from
LICENSORS.

 

    	5

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

3.2     
    SECOND SIGHT shall pay to LICENSORS within thirty (30) days of the EFFECTIVE DATE of this Agreement,
a nonrefundable processing fee of Twenty Thousand Dollars ($20,000). Such fee shall not be credited against future royalties
or other fees. 

 

3.3       
   SECOND SIGHT shall pay to LICENSORS a Five Thousand Dollar ($5,000) annual maintenance for the first seven
(7) years following the EFFECTIVE DATE and a Ten Thousand Dollar ($10,000) annual maintenance fee each year thereafter for
the remaining term of this Agreement. Such fees shall be due within thirty (30) days of each anniversary of the EFFECTIVE
DATE of this Agreement. Such fee shall not be credited against future royalties or other fees.

 

3.4       
   SECOND SIGHT shall pay to LICENSORS, a running royalty, for LICENSED PRODUCT(S) sold or leased by SECOND
SIGHT, AFFILIATED COMPANIES, and SUBLICENSEES for the term of this Agreement. Said royalty shall be calculated as a
percentage of NET SALES as set forth below:

 

	CUMULATIVE NET SALES	 	ROYALTY RATE
	Up to $25,000,000	 	3.0%
	$25,000,000 to $50,000,000	 	2.5%
	Over $50,000,000	 	2.0%

 

Should SECOND SIGHT be required
to pay royalties to a third party on any patent rights not licensed hereunder ("Other Royalties") in order to make, use,
sell or lease a particular LICENSED PRODUCT, SECOND SIGHT shall be entitled to credit half (50%) of such Other Royalties against
the running royalties due to LICENSORS pursuant to this Paragraph 3.4, provided that the running royalties shall not be reduced
below a royalty rate of one and a half percent (1.5%) of NET SALES. In addition to the running
royalty provisions above, SECOND SIGHT shall pay to LICENSORS twenty percent (20%) of all other revenue received by SECOND SIGHT
in consideration for a sublicense. Such consideration shall include any up-front, annual, milestone or other payments and value
above fair market value of any equity purchased by sublicensee. Consideration shall not include any research or development money
paid to SECOND SIGHT to conduct research. In the event that any
such consideration from a SUBLICENSEE is creditable against future running royalties due to SECOND SIGHT ("Creditable Fees"),
then any portion of Creditable Fees paid to LICENSORS shall be creditable against future running royalties due to LICENSORS from
the sales of LICENSED PRODUCTS by the SUBLICENSEE.

 

3.5          Upon obtaining a Pre-market
Approval or 510(k) exemption from the FDA, or equivalent marketing approval, of a LICENSED PRODUCT, SECOND SIGHT shall pay LICENSORS
a one-time milestone fee of One Hundred Fifty Thousand Dollars ($150,000), which is due within one-hundred eighty (180) days of
such regulatory approval.

 

    	6

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

3.6     
     SECOND SIGHT shall provide, within forty-five (45) days of the end of each June and December
after the first commercial sale of LICENSED PRODUCTS pursuant to this Agreement, a written report to LICENSORS of the amount
of LICENSED PRODUCTS sold, the amount of reductions to sales as allowed by Paragraph 1.4 herein, the total NET SALES of such
LICENSED PRODUCT(S), and the running royalties due to LICENSORS as a result of NET SALES by SECOND SIGHT, AFFILIATED
COMPANIES and SUBLICENSEES. Payment of

any such royalties due shall accompany such reports.

 

3.7    
     SECOND SIGHT shall make and retain, for a period of three (3) years following the period of
each report required by Paragraph 3.6, true and accurate records, files and books of account containing all the data
reasonably required for the full computation and verification of sales and other information required in Paragraph 3.6. Such
books and records shall be in accordance with generally accepted accounting principles consistently applied. SECOND SIGHT
shall permit the inspection and copying of such records, files and books of account by LICENSORS or their agents during
regular business hours upon ten (10) business days' written notice to SECOND SIGHT. LICENSORS shall keep all information
inspected confidential. Such inspection shall not be made more than once each calendar year. LICENSORS's failure to audit may
not be viewed to be a waiver of objection. All costs of such inspection and copying shall be paid by LICENSORS, provided that
if any such inspection shall reveal that a deficit error has been made in the amount equal to ten percent (10%) or more of
such payment, such costs shall be borne by SECOND SIGHT. SECOND SIGHT shall include in any agreement with its AFFILIATED
COMPANIES or SUBLICENSEES which permits such party to make, use, sell or lease the LICENSED PRODUCTS, a provision requiring
such party to retain records of sales of LICENSED PRODUCTS and other information as required in Paragraph 3.6 and
permit LICENSORS to inspect such records as required by this Paragraph 3.7. Each report made by SECOND SIGHT and all
AFFILIATED COMPANIES and SUBLICENSEES shall be final, binding and uncontestable unless a claim is made or a suit is filed not
more than three (3) years following the period of each report based on inspection and audit, a copy of which shall have been
given to SECOND SIGHT.

 

3.8          In
order to insure LICENSORS the full royalty payments contemplated hereunder, SECOND SIGHT agrees that in the event any
LICENSED PRODUCTS shall be sold or leased to a corporation, firm or association with which SECOND SIGHT shall have any
agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase
stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances), the
royalties to be paid hereunder for such LICENSED PRODUCTS shall be based upon the greater of: 1) the net selling price or
lease rate at which the purchaser or lessor of LICENSED PRODUCTS resells or leases such product to the end user; 2) the fair
market value of the LICENSED PRODUCTS as determined by (i) the price of products similar to LICENSED PRODUCTS sold by a
competitor of SECOND SIGHT in a similar market, (ii) the price of LICENSED PRODUCTS sold by SECOND SIGHT, an AFFILIATED
COMPANY, or a SUBLICENSEE, to third parties at arms length, i.e. NET SALES, or (iii) as reasonably negotiated in good faith
by the parties hereto; or 3) the net selling price or leasing rate of LICENSED PRODUCTS paid by the purchaser or lessor.

 

    	7

    	 

    

   

	Second  Sight, LLC
	License Agreement
	 

 

3.9
           Until SECOND SIGHT, an AFFILIATED COMPANY or a SUBLICENSEE
has achieved a first commercial sale of a LICENSED PRODUCT and received regulatory market approval, as appropriate, SECOND
SIGHT shall provide JHU within sixty (60) days of each anniversary of the EFFECTIVE
DATE, a full written report describing SECOND SIGHT'S efforts and progress toward achieving a first commercial sale. If
LICENSORS have questions concerning the content of these reports, such questions will be provided to SECOND SIGHT in writing.
SECOND SIGHT will respond in writing to LICENSOR's questions within forty-five (45) days from receipt by SECOND SIGHT.

 

3.10         Upon breach or default
of any of the terms and conditions of this Agreement, the defaulting party shall be given written notice of such default and a
period of sixty (60) days after receipt of such notice to correct the default or breach. If the default or breach is not corrected
within said sixty (60) day period, the party not in default shall have the right to terminate all or part of the Agreement. Nothing
herein shall limit any other rights or remedies at law or in equity for breach or default of any terms and conditions of this Agreement.

 

3.11          SECOND SIGHT may terminate
this Agreement, in part or in whole, for any reason, upon giving LICENSORS sixty (60) days written notice, and upon payment of
all amounts due to LICENSORS through the effective date of the termination.

 

3.12         Termination shall not
affect LICENSOR'S right to recover unpaid royalties or fees or reimbursement for patent expenses incurred prior to termination.

 

3.13
        All payments under this Agreement shall be made in U.S. Dollars. If any currency
conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using
the current exchange rate as reported in the Wall Street Journal on the last business day of the semi-annual reporting period
to which such royalty payments relate.

 

    	8

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

3.14         If SECOND SIGHT fails
to pay any amount due to LICENSORS in accordance with this Article 3, LICENSORS shall increase the amount due (in US Dollars) by
one and one half percent (1.5%). Such increase(s) shall compound monthly until such time as SECOND SIGHT has met the full financial
obligation due at the time of the next payment or invoice due date. SECOND SIGHT's payment of the fees in accordance with this
Paragraph 3.14 shall not preclude LICENSORS from any remedy under Paragraph 3.10 with respect to SECOND SIGHT's failure to make
required payments.

 

3.15
         Unless earlier terminated pursuant to Paragraph 3.10 or 3.11 above, this
Agreement shall remain in full force and effect in each
country throughout the world until the expiration of the last to expire patent included in PATENT RIGHTS in that particular
country.

 

ARTICLE 4 - DILIGENCE

 

4.1           SECOND SIGHT shall exercise
commercially reasonable efforts to develop and commercialize the LICENSED PRODUCTS using good scientific and business judgment.
SECOND SIGHT shall be deemed to have met this standard if it has satisfied the following milestones:

 

		a.	Develop a prototype LICENSED PRODUCT for clinical testing within five (5) years of the EFFECTIVE DATE of this Agreement.; and

 

		b.	Commence a Phase I clinical study of a LICENSED PRODUCT within six (6) years of the EFFECTIVE DATE of this Agreement.

 

Failure of SECOND SIGNT to meet any milestones set forth above in this subparagraph 4.1 shall be considered by
LICENSORS a breach of this Agreement provided that SECOND SIGHT can remedy any failure to meet the milestones described in this
Paragraph 4.1 by paying a fee to extend the milestone an additional year. Said fee shall be in the amounts listed below and shall
be payable within thirty (30) days of the date at which the milestone should have been met:

 

    	9

    	 

    

 

	Second  Sight, LLC
	License Agreement
	 

 

	Extension Term	 	Fee	 
	1st Year	 	$	10,000	 
	2nd Year	 	$	25,000	 
	3rd and each subsequent Year	 	$	50,000	 

 

ARTICLE 5 -PATENT PROSECUTION

 

5.1
          LICENSORS shall diligently file, prosecute, and maintain all patents
and patent applications specified under PATENT RIGHTS provided that SECOND SIGHT does not owe JHU any
payments or fees under this agreement that are past due. SECOND SIGHT, and its retained patent counsel, shall be provided
copies of all correspondence related to such patent
applications or issued patents in a timely fashion. SECOND SIGHT shall have the right to select the jurisdictions in which
patents are to be pursued and maintained and shall have reasonable opportunities to advise LICENSORS and shall cooperate with
LICENSORS in such filing, prosecution, and maintenance.

 

ARTICLE 6 - CONFIDENTIALITY

 

6.1
          If necessary, the parties will exchange information which they
consider to be confidential. The recipient of such information agrees to accept the disclosure of said information which is
marked as 'confidential' at the time it is sent to the recipient, and to employ all reasonable efforts to maintain the
information secret and confidential, such efforts to be no less than the
degree of care employed by the recipient to preserve and safeguard its own confidential information. The information shall
not be disclosed or revealed to anyone except patent counsel when a patent is to be pursued under the terms of this
Agreement and_employees of the recipient who have a need to know the information and who have entered into a secrecy
agreement with the recipient under which such employees are required to maintain confidential the proprietary information of
the recipient and such employees shall be advised by the recipient of the confidential nature of the information and that the
information shall be treated accordingly. The recipient's obligations under this Paragraph 6.1 shall not extend to any part
of the information:

 

    	10

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

		a.	that can be demonstrated to have been in the public domain or publicly known and readily available to the trade or the public
prior to the date of the disclosure; or

 

		b.	that can be demonstrated, from written records to have been in the recipient's possession or readily available to the recipient
from another source not under obligation of secrecy to the disclosing party prior to the disclosure; or

 

		c.	that becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized act by the
recipient; or

 

		d.	that is demonstrated from written records to have been developed by or for the receiving party without reference to confidential
information disclosed by the disclosing party.

 

The obligations of this Paragraph
6.1 shall also apply to AFFILIATED COMPANIES and/or SUBLICENSEES provided such information by SECOND SIGHT. JHU's, DUKE's, SECOND
SIGHT's, AFFILIATED COMPANIES', and SUBLICENSEES' obligations under this Paragraph 6.1 shall extend until three (3) years after
the termination of this Agreement.

 

    	11

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

ARTICLE 7- PATENT INFRINGEMENT

 

7.1
          Each party will notify the other promptly in writing when any
infringement by another is uncovered or suspected.

 

7.2
          SECOND SIGHT shall have the first right to enforce any patent within
PATENT RIGHTS against any infringement or alleged infringement thereof, and shall at all times keep LICENSORS informed as to
the status thereof. SECOND SIGHT may, in its sole judgment and at its own expense, take steps to enforce any patent within
PATENT RIGHTS and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof and
recover, for its account, any damages, awards or settlements resulting therefrom. This right to sue for infringement shall
not be used in an arbitrary or capricious manner. LICENSORS shall reasonably cooperate in any such litigation at SECOND
SIGHT's expense.

 

7.3
           If SECOND SIGHT elects not to enforce any patent within
the PATENT RIGHTS, then it shall so notify LICENSORS in writing within six (6) months of receiving notice that an
infringement exists, and LICENSORS may, in their sole judgment and at their own expense, take steps to enforce any patent and
control, settle, and defend such suit in a manner consistent with the terms and provisions hereof, and recover, for its own
account, any damages, awards or settlements resulting therefrom. This right to enforce any patent shall not be used in

an arbitrary or capricious manner.

 

7.4           Any recovery by SECOND
SIGHT under Paragraph 7.2 shall be deemed to reflect loss of commercial sales, and SECOND SIGHT shall pay to LICENSORS the following
percentages of the recovery net of all reasonable costs and expenses associated with each suit or settlement:

 

    	12

    	 

    

 

	Second  Sight, LLC
	License Agreement
	 

 

		(i)	For any compensatory damages or recovery, such damages or recovery shall be considered 'Profit' for the purposes of this Paragraph
7.4 and such 'Profit' shall be multiplied by a factor of not less than one (1.0) to convert the 'Profit' to 'Calculated NET SALES'.
Said factor shall be determined by dividing SECOND SIGHT's average NET SALES for LICENSED PRODUCTS over the period of infringing
sales divided by SECOND SIGHT's average cost of goods sold for LICENSED PRODUCTS over the period of infringing sales; and SECOND
SIGHT shall pay to JHU the royalty specified in Paragraph 3.4 as if the 'Calculated NET SALES' calculated pursuant to this Paragraph
7.4 were actual NET SALES of LICENSED PRODUCTS sold by SECOND SIGHT; and

 

		(ii)	For any other recovery, Fifteen percent (15%).

  

If the cost and expenses exceed the recovery,
then one-half (l/2) of the excess shall be credited against royalties payable by SECOND SIGHT to LICENSORS hereunder in
connection with sales in the country of such legal proceedings, provided, however, that any such credit under this Paragraph
7.4 shall not exceed fifty percent (50%) of the royalties otherwise payable to LICENSORS with regard to sales in the country
of such action in any one calendar year, with any excess credit being carried forward to future calendar years.

 

ARTICLE 8 -EXPORT CONTROLS

 

8.1     
     SECOND SIGHT acknowledges that it may be subject to United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes and other commodities (including the Arms
Export Control Act, as amended and the United States Department of Commerce Export Administration Regulations). The transfer
of such items may require a license from the cognizant agency of the United States Government and/or written assurances by
SECOND SIGHT that SECOND SIGHT shall not export data or commodities to certain foreign countries without prior approval of
such agency. LICENSORS neither represent that such a license shall not be required nor that, if required, it shall be
issued.

 

    	13

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

ARTICLE 9 - CLINICAL TRIALS
& RESEARCH OPTION

 

9.1    
     JHU has the first option to conduct Phase I clinical studies and participate in all future
clinical studies.Terms of clinical study agreements shall be negotiated separate from this Agreement.

 

9.2    
     For a period of five (5) years following the EFFECTIVE DATE, SECOND SIGHT shall have the first
option to fund research in the FIELD at JHU in the
laboratories of Drs. de Juan or Humayun.

  

ARTICLE 10- MISCELLANEOUS

 

10.1    
  All notices pertaining to this Agreement shall be in writing and sent certified mail, return receipt requested,
to the parties at the following addresses or such other address as such party shall have furnished in writing to the other
party in accordance with this Paragraph 10.1:

 

	FORJHU:	Director
	 	Office of Technology Licensing 

The Johns Hopkins University 

School ofMedicine
	 	111 Market Place, Suite 906
	 	Baltimore, MD 21202
	 	 
	DUKE:	Attn: Agreements Administrator

 Duke University
	 	Office of Science & Technology
	 	P.O. Box 90083
	 	Durham, NC  27708

 

    	14

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

	FOR SECOND SIGHT:	Robert J. Greenberg, M.D., Ph.D.
	 	President
	 	Second Sight, LLC
	 	28460 Avenue Stanford, #200
	 	Valencia, California  91355

 

10.2       ·All written progress
reports, royalty and other payments, and any other related correspondence shall be in writing and sent to the appropriate person
specified in Paragraph 10.1 above or such other addressee which LICENSORS may designate in writing from time to time. Checks are
to be made payable to "The Johns Hopkins University". JHU shall be responsible for
accounting to DUKE.

 

10.3         This Agreement is binding
upon and shall inure to the benefit of LICENSORS, their successors and assignees and shall not be assignable to another party without
the written consent of LICENSORS, which consent shall not be unreasonably withheld, except that SECOND SIGHT shall have the right
to assign this Agreement to another party without the consent of LICENSORS in the case of the sale or transfer by SECOND SIGHT
of all, or substantially all, of its assets relating to the LICENSED PRODUCTS, to that party.

 

10.4        In
the event that any one or more of the provisions of this Agreement should for any reason be held by any court or authority
having jurisdiction over this Agreement, or over any of the parties hereto to be invalid, illegal or unenforceable, such provision
or provisions shall be reformed to approximate as nearly as possible the intent of the parties, and if unreformable, shall be divisible
and deleted in such jurisdictions; elsewhere, this Agreement shall not be affected.

 

10.5        SECOND SIGHT
agrees that all packaging containing individual LICENSED PRODUCTS sold by SECOND SIGHT, AFFILIATED COMPANIES and SUBLICENSEES
of SECOND SIGHT will be marked with the number of the applicable patent(s) licensed hereunder in accordance with each
country's patent laws.

 

10.6   
   All disputes arising out of or related to this Agreement, or the execution, performance, enforcement,
breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted, and applied in
accordance with the laws of the State of Maryland, except that questions affecting the construction and effect of any patent
shall be determined by the law of the country in which the patent shall have been granted. 

 

10.7   
      SECOND SIGHT shall not use the names or trademarks of DUKE UNIVERSITY or THE JOHNS
HOPKINS UNIVERSITY or THE JOHNS HOPKINS HEALTH SYSTEM or any of their constituent parts, such as the Johns Hopkins Hospital
or any contraction thereof or the name of inventors of PATENT RIGHTS in any advertising, promotional, sales literature or
fundraising documents without prior written consent from an officer of JHU and DUKE.
SECOND SIGHT shall allow at least seven (7) business days notice of any proposed public disclosure for DUKE's and JHU's
review and comment or to provide written consent. LICENSORS shall not use any trademarks or service marks now or hereafter
used or adopted by SECOND SIGHT whether or not in connection with LICENSED PRODUCTS without the prior written consent of an
officer of SECOND SIGHT.

 

    	15

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

10.8      
  LICENSORS warrant that they have good and marketable title to their respective interest in the
inventions claimed under PATENT RIGHTS with the exception of certain retained rights of the United States government as
set forth in P.L. 96-517, as amended by P.L. 98-620,
and as set forth in 37 CFR Part 401. JHU and DUKE do not warrant the validity of any patents or that practice under
such patents shall be free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 10.8, SECOND SIGHT, ITS
AFFILIATED COMPAN1ES AND SUBLICENSEES AGREE THAT THE PATENT RIGHTS ARE PROVIDED "AS IS", AND THAT LICENSORS MAKE
NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE PERFORMANCE OF LICENSED PRODUCTS INCLUDING THEIR SAFETY, EFFECTIVENESS,
OR COMMERCIAL VIABILITY. LICENSORS DISCLAIM ALL WARRANTIES WITH REGARD TO PRODUCT(S) AND DEVICES LICENSED UNDER THIS
AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANT ABILITY AND FITNESS FOR ANY
PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, LICENSORS ADDITIONALLY DISCLAIM ALL OBLIGATIONS
AND LIABILITIES ON THE PART OF LICENSORS, THEIR INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT,
SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS' AND EXPERTS' FEES, AND COURT COSTS (EVEN IF LICENSORS HAVE BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF
THE PRODUCT(S) AND INVENTION(S) LICENSED UNDER THIS AGREEMENT. SECOND SIGHT AND SUBLICENSEES ASSUME ALL RESPONSIBILITY
AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT AND SERVICE MANUFACTURED, USED, OR SOLD BY SECOND SIGHT, ITS
SUBLICENSEES AND AFFILIATED COMPANIES WIDCH IS A LICENSED PRODUCT AS DEFINED IN THIS AGREEMENT.

 

10.9   
      JHU, DUKE, and the inventors of PATENT RIGHTS will not, under the provisions of this
Agreement or otherwise, have control over the manner in which SECOND SIGHT or its SUBLICENSEES or those operating for its
account or third parties who purchase LICENSED PRODUCTS from any of the foregoing entities, practice the inventions of
LICENSED PRODUCTS. SECOND SIGHT shall defend and hold DUKE, JHU, The Johns Hopkins Health Systems, officers, inventors of
PATENT RIGHTS, agents, faculty, employees and students harmless as against any judgments, fees, expenses, or other costs
arising from or incidental to any product liability or other lawsuit, claim, demand or other action brought as a consequence
of the practice of said inventions by any of the foregoing entities, whether or not LICENSORS or said inventors, either
jointly or severally, is named as a party defendant in any such lawsuit. Practice of the inventions covered by LICENSED
PRODUCTS, by AFFILIATED COMPANIES or an agent or a SUBLICENSEES or a third party on behalf of or for the account of SECOND
SIGHT or by a third party who purchases or leases LICENSED PRODUCTS from SECOND SIGHT, shall be considered SECOND SIGHT's
practice of said inventions for purposes of this Paragraph 10.9. The obligation of SECOND SIGHT to defend and indemnify as
set out in this Paragraph 10.9 shall survive the termination of this Agreement.

 

    	16

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

10.10       Prior
to initial human testing or first commercial sale of any LICENSED PRODUCTS as the case may be in any particular
country, SECOND SIGHT shall establish and maintain, in each country in which SECOND SIGHT, AFFILIATED COMPANIES, or
SUBLICENSEES shall test or sell LICENSED PRODUCTS, product liability or other appropriate insurance coverage appropriate to
the risks involved in marketing LICENSED PRODUCTS and will at the request of LICENSORS present evidence to LICENSORS that
such coverage is being maintained. Upon LICENSORS's request, SECOND SIGHT will furnish LICENSORS with a Certificate of
Insurance of each product liability insurance policy obtained. JHU and
DUKE shall each be listed as additional insured parties in SECOND SIGHT's said insurance policies.

 

10.11       LICENSORS may
publish manuscripts, abstracts or the like describing the PATENT RIGHTS and inventions contained therein provided SECOND
SIGHT is given sixty (60) days written notice prior to submission for publication and provided confidential information of
SECOND SIGHT as defined in Paragraph 6.i, is not included except with prior written permission from SECOND SIGHT.

 

10.12       This Agreement constitutes
the entire understanding between the parties with respect to the obligations of the parties with respect to the subject matter
hereof, and supersedes and replaces all prior agreements, understandings, writings, and discussions between the parties relating
to said subject matter.

 

10.13       This Agreement may
be amended and any of its terms or conditions may be waived only by a written instrument executed by the authorized officials of
the parties or, in the case of a waiver, by the party waiving compliance. The failure of either party at any time or times to require
performance of any provision hereof shall in no manner affect its right at a later time to enforce the same. No waiver by either
party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition
or term or of any other condition or term.

 

    	17

    	 

    

  

	Second  Sight, LLC
	License Agreement
	 

 

10.14  
   This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto
and their respective successors and permitted assigns. 

 

10.15   
   Upon termination of this Agreement for any reason, Paragraphs 3.11, 3.12, 6.1, 10.7, 10.8, 10.9, and
10.10 shall survive termination of this Agreement.

 

INWITNESS
WHEREOF the respective parties hereto have executed this Agreement by their duly authorized officers on the date appearing below
their signatures. 

 

	THE JOHNS HOPKINS UNIVERSITY	 	SECOND SIGHT, LLC
	SCHOOL OF MEDICINE	 	 
	 	 	 

 

	By		 	By	/s/
    Robert J. Greenberg
	 	WJ.D. Tew, Ph.D.	 	 	Robert J.
    Greenberg, M.D, Ph.D.
	 	Executive Director,	 	 	President
	 	Licensing & Business Development	 	 	
	 	 	 	 	 
	Date:	October 24,
    2000	 	Date:	9/5/00

 

	DUKE UNIVERSITY	 
	 	 
	By	 
	 	Robert L. Taber	 
	 	Associate  Vice  Chancellor	 
	Date: 	00-00-00	 

    	18

    	 

    

 

	Second  Sight, LLC
	License Agreement
	 

 

I have read and agree
to abide by the terms of this Agreement

 

	 	 	 
	 	Eugene de Juan, Jr., M.D.	 
	 	 	 
	By	/s/ Mark S.
    Humayun	 
	 	Mark S. Humayun, M.D., Ph.D.	 
	 	 	 
	By	 	 
	 	Howard Phillip&, M.D.	 

 

    	19

    	 

    

  

Appendix A

 

LIST OF IMPROVEMENTS 

 

    	20

    	 

    

  

AMENDMENT

 

This is an amendment to the Exclusive
License Agreement by and between Second Sight, LLC, Duke University and Johns Hopkins University dated October 24, 2000 (the "Agreement").

 

Whereas Drs. Mark Humayun
and Eugene de Juan have left JHU along with most of the members of the "laboratory of
Drs. Eugene de Juan or Mark Humayun" (the "Laboratory");

 

Dr. Gislin Dagnelie once part
of the Laboratory remains at JHU and continues the research of the Laboratory;

 

Second Sight, LLC was merged
into Second Sight Medical Products, Inc. which is its successor in interest; and

 

Parties have changed their addresses for notices;

 

Therefore the parties to the
Agreement wish to amend the Agreement to reflect the aforesaid changes.

 

	1.	All defined terms in the Agreement shall apply to this Amendment.

 

	2.	Amend the prean1ble to replace "Second Sight, LLC" with "Second Sight Medical Products, Inc".

 

	3.	Amend paragraph 1.10 to replace "in the laboratory of Drs. Eugene de Juan or Mark Humayun" with "in the laboratory
Drs. Eugene de Juan, Mark Humayun or Gislin Dagnelie".
	 	 

	4.	Amend paragraph 10.1 to replace the addresses for notices with:

 

	 	For JHLJ:	Director
	 	 	Office of Licensing and Technology Development
	 	 	100 North Charles Street 

Suite 500
	 	 	Baltimore, MD 21201
	 	 	 
	 	For Second Sight	Robert J. Greenberg, M.D. Ph.D. President
	 	 	Second Sight Medical Products, Inc.

 12744 San Fernando Road
	 	 	Building 3
	 	 	Sylmar CA 91342

 

    	 

    	 

    

  

In witness whereof the respective
parties hereto have executed this Amendment by their duly authorized officers

 

	Second Sight Medical Products, Inc.	 	Johns Hopkins University
	 	 	
	/s/ Robert J. Greenberg	 	/s/ R. Keith Baker
	Robert J. Greenberg, M.D. Ph.D. 	 	R. Keith Baker
	President	 	Director
		 	Office of Licensing and 

Technology Development
	 	 	 
	 		 	 	
	Date	10/29/04	 	Date	10/27/04
	 	 	 
	Duke University	 	 
	 	 	 
	/s/ Robert L. Taber	 	 
	Robert L. Taber	 	 
	Associate- Vice Chancellor	 	 

 

		 	 	 
	Date	00-00-00	 	 

 

    	2Exhibit 10.12

 

COST REIMBURSEMENT CONSORTIUM RESEARCH AGREEMENT

 

This COST
REIMBURSEMENT CONSORTIUM RESEARCH AGREEMENT (this "Agreement") is made by and between Doheny Eye Institute ("DEI"),
a California nonprofit public benefit corporation, located at 1450 San Pablo Street #3000, Los Angeles, CA 90033 and Second
Sight Medical Products, Inc. ("SSMP"), a California corporation, with its
principal place of business at 12744 San Fernando Road, Building 3, Sylmar, CA, 91342, as of June 1, 2006 (the "Effective
Date").

 

WHEREAS,
scientists at DEI have been working in collaboration with SSMP and the University of Southern California ("USC")
scientists to test and support the development of microelectronic visual prosthetic implants and related external support
systems (the "Research Products");

 

WHEREAS,
DEI and SSMP previously entered into a Research Agreement dated April 9, 2002 (the "Prior
Agreement") concerning certain prior work performed in pursuit of the foregoing collaboration; and

 

WHEREAS,
DEI and SSMP believe that continuing the foregoing collaboration through the research programs contemplated by this Agreement is
of mutual interest and benefit to the parties and will further the instructional and research objectives of DEI in a manner consistent
with its status as a nonprofit, tax-exempt institution;

 

NOW, THEREFORE, the parties hereto agree as follows:

 

1.        STATEMENTS
OF WORK.

 

a.           Current
Research Projects.  DEI agrees to use c01mnercially reasonable efforts to perform the research projects relating
to the Research Products (each a "Research Project") set forth in each of
the Statements of Work (each an "SOW") attached hereto. The parties acknowledge
that the SOW for the first Research Project is set forth under Exhibit A-1 and that such Research Project is being funded by an
NIH - Bioengineering Research Partnerships ("BRP") grant
number R01 EY012893-06A1, entitled "Research/Development of Artificial Retinas for the Blind," awarded to Principal Investigator
Robert Greenberg of SSMP, as set forth in that certain Notice of Grant Award issued November 2, 2006.

 

b.           Additional
Research. The parties may agree to work on one or more additional Research Projects from time to time by preparing a separate
SOW for each such additional Research Project signed by both parties that sets forth, at a minimum, the scope of such Research
Project, the Period of Performm1ce (as defined in Section 3 below), the cost estimates, projected budget, or other consideration
to be paid, timetable, reporting, and such other information as is set forth for the first SOW attached hereto as Exhibit A-1,
to the extent applicable. Each new SOW shall be attached as a separate Exhibit A-"X" to this Agreement.

 

    	1

    	 

    

 

c.           Revisions.
The parties understand and acknowledge that, from time to time, the parties may desire to revise the scope, timetable, Period of
Performance, reporting, or other requirements of any Research Project set forth in the applicable SOW. Any such revisions shall
be made only by mutual written agreement signed by both parties amending the applicable SOW. In addition, the cost estimates and/or
projected budget for any Research Project may be revised as provided in Section 5 below. SSMP shall promptly report any such revision
to the NIH or other applicable agency funding any Research Project hereunder, or obtain the NIH's or such agency's consent to any
such revision, in each case to the extent required by the rules governing the applicable grant, including without limitation any
Special Conditions or the NIH Grants Policy Statement, as each such tem1 is defined in Section 8 below.

 

d.           Materials.
SSMP shall use reasonable commercial efforts to provide to DEI such devices and other materials as may be set forth in each SOW.

 

2.           PRINCIPAL
INVESTIGATOR ("PI").

 

Each Research Project will be
supervised by a PI identified in the applicable SOW. The PI for the Research Project set forth in Exhibit A-1 initially
shall be Mark Humayun, M.D., Ph.D. If for any reason no specified person is able to continue to serve as a PI for a particular
Research Project and a successor PI acceptable to both DEI and SSMP is not available, either the affected SOW or, if all SOWs are
affected, this Agreement, may be terminated by either party, as provided in Section 21.d. below. The parties may include in each
SOW a list of the DEI Personnel (as defined below) the parties anticipate will work on the Research Project covered by that SOW
as of the effective date of the SOW for informational purposes only; the parties acknowledge that not all DEI Personnel listed
in an SOW may work on the applicable Research Project and that DEI Personnel who are not listed in an SOW may work on the applicable
Research Project. For purposes of this Agreement, "DEI Personnel" means those persons who DEI treats as employees
for state m1d federal tax reporting purposes, regardless of whether or not such persons receive additional compensation from other
parties, including but not limited to USC. For avoidance of doubt, DEI Personnel includes, without limitation, the following people:
Mark Humayun, James Weiland, Rajat Agrawal, Alan Horsager, Lucien Laude, Konstantin Kolev Brooke Bassinger, Adrian Rowley, Lindy
Yow, Gerald Chader, Saloomeh Saati, Sonia Cisneros, Luiz Lima, Naoki Matsuoka and Hossein Ameri. Dilek Guven was a former employee
of DEI (employed from 7/8/02- 6/23/04) Gilda Fujii, was a former employee of DEI (employed from 9/12/01- 6/30/04), Ricardo Freda
was a former employee of DEI (employed from 12/1/03- 9/1/06), Eugene De Juan was a former employee of DEI (employed from 8/16/01-
10/10/05) and Ashish Ahuja was a fom1er USC graduate student (from 711/05 to 5/31107) all of whom shall be considered DEI Personnel
for inventions made during their employment and student status, respectively.

 

3.         PERIOD
OF PERFORMANCE.

 

Each SOW shall
set forth the period of performance for the Research Project to be conducted pursuant thereto (each a "Period of Performance").
Each Period of Performance will be subject to renewal or extension only by mutual written agreement of both parties as provided
in Section l.c.; DEI shall not be required to perform any Research Project beyond the applicable Period of Performance without
its prior written agreement.

 

    	2

    	 

    

 

4.            REPORT
OF WORK.

 

Progress
reports for each Research Project will be prepared by the applicable PI in
accordance with the terms of the applicable SOW and shall be due to SSMP on the schedule set forth in the applicable SOW.
SSMP shall provide DEI with written acceptance of each such report within thirty (30) days of receipt thereof, or provide specific
grounds for non-acceptance. SSMP warrants that all reports submitted by DEI to SSMP will then be submitted to the NIH or other
applicable agency to the extent required by the grant funding the Research Project to which the report pertains.

 

5.           REIMBURSEMENT
OF COSTS.

 

In consideration
of the services to be performed by DEI in connection with each Research Project, SSMP will reimburse DEI for all direct and indirect
costs incurred in the performance of such services, which costs for each Research Project shall not exceed the total estimated
cost for such Research Project as may be set forth in the applicable SOW without written authorization from SSMP. In the event
the direct and indirect costs incurred in the performance of any Research Project exceed the total estimated cost for such Research
Project or any other change in the projected budget is required by DEI to complete the Research Project, and SSMP does not authorize
additional reimbursement of DEI's costs or any such change, DEI shall have the option to immediately terminate the applicable SOW
or, if all SOWs are affected, this Agreement, as provided in Section 21.e. below.

 

6.         COST
PAYMENTS.

 

a.           Invoices.  Payments
made by SSMP under Section 5 will be made on receipt of monthly invoices from DEI itemized according to the budget detail shown
in the applicable SOW. DEI shall submit invoices not more frequently than on a monthly basis for costs incurred to the date of
the invoice. Each invoice must show the amounts expended in the current period, and cumulatively to date by line item budget categories.
Invoices shall be supported by a written record indicating DEI Persom1el working on the applicable Research Project including hours
worked by each DEI Personnel, and copies of invoices or receipts for all costs amounting to more than $1,000 in a given month.
Due to this additional effort, SSMP agrees to reimburse DEI $30.00 per hour for generating said written records (not to exceed
$3,600 per year). If additional information or documentation is required in connection with any invoice, it shall be specified
elsewhere in this Agreement or in the applicable SOW. SSMP will pay all invoices within thirty (30) days of the date of an invoice,
provided invoices are for work performed not more than 60 days prior to the invoice date. SSMP shall have additional time to review
invoices equal to the period any invoice is delayed beyond 60 days after the date work is preformed. A sample invoice will be attached
to each SOW. All payments under this Agreement shall be made in U.S. dollars. Invoices should be submitted to:

 

    	3

    	 

    

 

Kathy London

Director,
Finance & Administration

Second Sight Medical Products, Inc.

12744 San Fernando Road,
Bldg 3

Sylmar, California 91342

 

b.           Foreign
Currency. If any currency conversion shall be required in connection with the reimbursement of any costs or payment of any
royalties or other an1ounts hereunder, such conversion shall be made by using the current exchange rate reported in the Wall
Street Journal on the last business day of the reporting period to which such reimbursement or payments relate.

 

c.           Late
Payments. If SSMP fails to pay the full amount of any invoice submitted hereunder, the unpaid amounts will accrue a late fee
daily equivalent to one percent (1%) per month (or, if lower, the maximum rate permitted by
applicable law) from the date initially due until the date actually paid. Said late fees are to be paid by SSMP with non-NIH funds
and are in addition to the contract ceiling.

 

d.           Disputes.
SSMP acknowledges that DEI is subject to OMB Circulars A-110 and A-133. If there is a dispute regarding any invoice and the
total amounts invoiced do not exceed the total authorized, SSMP shall pay the invoice and the parties will work diligently to resolve
the dispute. The parties agree to submit any unresolved dispute to binding arbitration in accordance with Section 24.b. below.
After agreement is reached or arbitration completed, DEI will return to SSMP any funds that were agreed or found to be improperly
charged within thirty (30) days. If DEI is found by the arbitrator to have invoiced SSMP in bad faith, the refunded amounts will
be subject to the late payment provisions of Section 6.c. above. If the parties are unable to resolve a dispute, either party shall
have the right to bring any billing or other disputes arising hereunder to the attention of the NIH or other applicable agency
funding a Research Project hereunder, provided that the other party is already on notice of such dispute.

 

7.        COST
RECORDS AND AUDITS.

 

All costs
incurred in DEI's performance of this Agreement will be subject to audit in accordance with this Section 7 and OMB Circulars A-110
and A-133 to the extent applicable. SSMP agrees to cooperate with DEI in all respects to enable compliru1ce with such OMB Circulars.
SSMP may, upon no less than thirty (30) days prior written notice to DEI and not more than once per calendar year during the term
of this Agreement, cause a mutually agreed upon independent Certified Public Accountant to inspect the records of DEI during normal
business hours reasonably related to the calculation of the reported costs. The fees and expenses charged by such Certified Public
Accountant in connection with such inspection shall be paid by SSMP. Both parties shall be entitled to receive copies of the reports
of the auditors. Should any such audit result in disallowances, SSMP shall determine whether or not the disallowances will be accepted
or appealed. In the event that the disallowances are sustained, DEI will return to SSMP any funds which are disallowed and which
have already been paid. Nothing in this Section, however, shall prevent a party from pursuing any and all administrative and judicial
remedies that may be available and permitted by this Agreement. SSMP agrees to maintain the confidentiality of any and all audit
proceedings, findings, reports, and corrective actions.

 

    	4

    	 

    

 

8.        CONDITIONS
OF GRANTS.

 

a.           NIH
Grants Policy Statement & Special Conditions.   To the extent any Research
Project is funded by a grant from the NIH, the parties agree to comply with the public policy requirements included in the NIH
Grants Policy Statement as amended as of the Effective Date (the "NIH Grants Policy Statement")
to the extent applicable to such Research Project, including without limitation with respect to: (1) debarment and
suspension; (2) drug-free workplace; (3) lobbying; (4) financial conflict of interest (including without limitation 42 C.P.R.
Part 50, Subpart F, "Responsibility of Applicants for Promoting Objectivity in Research for Which PHS Funding is Sought");
(5) research misconduct and instruction in the responsible conduct of research; (6) delinquent federal debt; (7) human pluripotent
stem cell research; (8) human subjects; (9) research on transplantation of fetal tissue; (10) ve1iebrate animals; (11) inclusion
of women, children, and minorities in clinical research; (12) age discrimination; (13) civil rights; (14) sex discrimination;
and (15) handicapped individuals; in each case to the extent applicable to each Research Project. In addition, the parties agree
to comply with any "Special Conditions of the Prime Award" ("Special Conditions")
that may be applicable to the NIH grant funding any such Research Project (if ally). Except as may be expressly stated
in this Agreement or any applicable SOW, the administrative policies of DEI shall govern the administration of each Research Project
hereunder, in accordance with the NIH Grants Policy Statement (if applicable) and any applicable Special Conditions. Without limiting
the generality of the foregoing, the parties agree that DEI's financial conflict of interest requirements shall apply to all of
the PI's who are DEI personnel hereunder.

 

b.           Carry
Forward.   SSMP agrees to carry forward unexpended funds to the subsequent budget period.

 

c.           Other
Grants. If any Research Project is funded by a grant from a governmental or other agency other than the NIH, the parties agree
to comply with the terms of any such grant.

 

d.           Conflicts.
In the event of any conflict between this Agreement, on the one hand, and any mandatory provisions of the Special Conditions, the
NIH Grants Policy Statement, and/or any other applicable grant, on the other, such mandatory provisions of the Special Conditions,
the NIH Grants Policy Statement, and/or such grant shall take precedence, with the Special Conditions taking precedence over the
NIH Grants Policy Statement in the event of any conflict between them.

 

9.        ROYALTIES.

 

a.           Royalty
Rate. In consideration of the rights granted to SSMP in Section 15.g below, SSMP shall pay DEI a cash royalty on all Net Sales
of Licensed Products (as defined in Section 9.b. below), payable on a monthly basis in an amount equal to 0.5% of Net Sales. The
foregoing royalty shall be in lieu of, rather than in addition to, any royalty under the Prior Agreement, such that the total royalty
owed DEI by SSMP shall not exceed 0.5% of Net Sales.

 

b.           Definitions.         For
purposes of this Agreement, the following terms, when used herein with initial capitalization, shall have the following meanings:

 

    	5

    	 

    

 

(1)         "Net
Sales" shall mean all monetary amounts and other things of value received by any of the SSMP Parties (as defined
below) from the manufacture, use, sale, lease, or license of Licensed Products (as defined below), including without limitation
advances, fees, royalties, milestone payments, and gross sales revenues, less only reasonable trade discounts, broker and agent
fees, refunds, retums and recalls, taxes (U.S. sales tax, foreign taxes incident to sale, but excluding income taxes) and reasonable
freight and transportation charges, in each case only to the extent such amounts are actually allowed or paid by any of the SSMP
Parties and otherwise would be includable in Net Sales hereunder. In the event that the applicable product sold is a system comprising
a combination of one or more Licensed Products and other components, Net Sales for purposes of Section 9.a. above shall be calculated
by multiplying the Net Sales of the system by the fraction A/B,
where 'A' is the fully burdened standard manufacturing cost of the Licensed Products, and 'B' is the fully burdened
manufacturing cost of the entire system. Net Sales shall exclude sales of Licensed Products by any SSMP Parties to each other.
SSMP will provide with each monthly payment, a written report to DEI of the amount of Licensed Products manufactured, sold, used,
leased or licensed by any of the SSMP Parties, the expenses and charges relevant to calculating Net Sales, and all other information
relevant in calculating the royalties due to DEI as a result of Net Sales by any of the SSMP Parties.

 

(2)         "Affiliate"
means, with respect to a party, any person or entity that Controls, is Controlled by, or is under common Control with,
such party. For purposes of the previous sentence, "Control" means: (i) with
respect to an entity, the direct or indirect ownership of more than fifty percent (50%) of the voting securities, general partnership
interests, profits interests, membership interests, or other equivalent ownership interests of or in such entity, or the power
to direct or cause the direction of the management or policies of such entity, whether by ownership of voting securities, by contract,
or otherwise; and (ii) with respect to a person, the power to control the affairs of such person, whether through an employment
relationship or other contractual relationship.

 

(3)         "SSMP
Parties" means SSMP and its Affiliates and sublicensees, or any of their respective permitted assigns or successors
in interest.

 

(4)         "Licensed
Products" shall mean any Research Products, materials therefor, or components thereof, the manufacture, use, importation,
distribution, sale or other exploitation of which would constitute infringement or misappropriation of any DEI IP, and/or Joint
IP (as each such term is defined below) but for the license, whether exclusive or non-exclusive, to SSMP of any DEI IP or Joint
IP pursuant to Section 15.g. below or for SSMP's ownership interest in any Joint IP pursuant to Section 15.b. below. For the avoidance
of doubt, Licensed Products do not include, and the license granted to SSMP in Section 15.g below does not extend to, any products,
materials, or components not constituting microelectronic visual prosthetic implants, related external support systems, materials
therefor, or components thereof.

 

    	6

    	 

    

 

10.      ROYALTY
RECORDS AND AUDITS.

 

SSMP shall
make and retain, for a period of three years following the period of each report required by Section 9 above, true, accurate, and
complete records, files, and books of account containing all the data reasonably required for the full computation and verification
of sales of Licensed Products and other information required by Section 9, as well as of compliance with this Agreement. Such books
and records shall be in accordance with generally accepted accounting principles consistently applied. SSMP shall permit the inspection
and copying of such records, files and books of account by DEI or its agents during regular business hours upon ten (10) business
days' written notice to SSMP. DEI shall keep all information inspected confidential as Confidential Information under Section 12
of this Agreement. Such inspection shall not be made more than once each calendar year. SSMP shall pay any unpaid or underreported
royalties or other amounts identified in such inspection promptly upon request. All costs of such inspection and copying shall
be paid by DEI, unless the amounts actually paid by SSMP are determined to be less than ninety-five percent (95%) of the amount
payable under this Agreement in any consecutive twelve (12) month period, in which case SSMP shall immediately pay the reasonable
fees and expenses for such inspection, along with the an1ount of such underpayment plus interest at an annual rate of eleven percent
(11%). SSMP shall include in any agreement with any other SSMP Parties which permits such party to make, use, sell, license, or
lease the Licensed Products, a provision requiring such party to retain records of sales of Licensed Products and other information
as required by Section 9 and as required to verify compliance with such agreement, and to permit DEI to inspect such records as
required by this Section.

 

11.        TITLE
TO EQUIPMENT.

 

Title to
equipment purchased by DEI pursuant to the terms of this Agreement or any SOW shall vest in DEI upon acquisition, except that,
with respect to any equipment purchased with funds from a grant provided by the NIH, the NIH may have the right to require transfer
of title to the equipment with an acquisition cost of $5,000 or more to the U.S. Government or to an eligible third party named
by the NIH awarding office under the conditions specified in 45 C.P.R. 74.34(h). If the NIH has such a right, the NIH may exercise
such right within one hundred twenty (120) days of the completion or termination of the applicable grant or within one hundred
twenty (120) days of receipt of an inventory, as provided in 45 C.P.R. 74.34(h)(2), whichever is later.

 

12.         CONFIDENTIAL
INFORMATION.

 

a.           Disclosure.
Either party (in that capacity, the "Discloser") may disclose information
to the other party (in that capacity, the "Recipient") about the Discloser's
business, finances, technology, persom1el, collaborators, clients, suppliers, licensors, or licensees that derives independent
economic value from not being generally known or is otherwise of a proprietary and confidential nature and that: (i) if disclosed
other than orally or by inspection, is clearly marked as "confidential" or "proprietary"; (ii) if disclosed
orally or by inspection, is identified by the Discloser as being "confidential" or "proprietary" at the time
of initial discloser to the Recipient and, within thirty (30) days of disclosure, confirmed in writing as such (with sufficient
specificity to reasonably identify such information); or (iii) otherwise, by the nature of the circumstances surrounding the disclosure,
ought to be understood by the Recipient in good faith to be treated as confidential (collectively, "Confidential
Information").

 

    	7

    	 

    

 

b.           Obligations.   The
Recipient agrees to accept the disclosure of Confidential Information and to employ all reasonable efforts to maintain the Confidential
Information secret and confidential, such efforts to be no less than the degree of care employed by the Recipient to preserve and
safeguard its own Confidential Information of a similar nature. The Recipient shall not use or copy any Confidential Information
of the Discloser except to the extent necessary to perform its obligations and exercise its rights under this Agreement. The Recipient
shall not disclose or otherwise reveal the Confidential Information to any third party except: (i) as required as part of a patent
application or patent when a patent is to be pursued under the terms of this Agreement; (ii) on a "need to know" basis
under an obligation of confidentiality to its legal counsel, accountants, banks and other financing sources and their advisors;
(iii) to other participants in a grant funding any Research Project hereunder, who are identified in an SOW as such (each a "Grant
Participant") to the extent it is necessary for a party to disclose information in furtherance of the Research
Project under such grant and provided that such Grant Participant has signed a confidentiality agreement with the Recipient at
least as protective of the Discloser's Confidential Information as this Section and has been advised by the Recipient of the confidential
nature of the Confidential Information and that the information shall be treated accordingly; (iv) pursuant to any applicable DEI
compliance programs; and (v) to employees and independent contractors of the Recipient and its Affiliates who have a need to know
the information, provided that such employees and independent contractors have entered into a confidentiality agreement with the
Recipient at least as protective of the Discloser's Confidential Information as this Section and have been advised by the Recipient
of the confidential nature of the Confidential Information and that the information shall be treated accordingly.

 

c.           Exceptions.
The Recipient's obligations under this Section shall not extend to any part of the Confidential Information that:

 

(1)         can
be demonstrated to have been in the public domain or publicly known and readily available to the trade or the public prior to the
date of the disclosure;

 

(2)         can
be demonstrated from bona fide written, dated records to have been, prior to initial disclosure by the Discloser, in the
Recipient's possession free of any confidentiality obligation or readily available to the Recipient from another source not under
any confidentiality obligation;

 

(3)         becomes
part of the public domain or otherwise publicly known by publication or other means, not due to any unauthorized act by the Recipient
nor any act of another third party which Recipient should have known was unauthorized, but only from and after such time as such
Confidential Information becomes publicly known; or

 

(4)         is
the same as information that can be demonstrated from bonafide written, dated records to have been developed by or for the
Recipient without access or reference to Discloser's Confidential Information.

 

    	8

    	 

    

 

d.           Required
Disclosures.   This Agreement shall not prohibit the Recipient from disclosing any Confidential Information
of the Discloser to the extent required by a court, administrative agency, or other tribunal of competent jurisdiction, or otherwise
to the extent required by applicable law, provided however that in such case the Recipient shall promptly inform the Discloser
of any such obligation so that the Discloser may seek a protective order or other legal remedy, cooperate with the Discloser in
pursuing any such remedy, and disclose only that portion of the Confidential Information that, in the opinion of its legal cmmsel,
is required to be disclosed.

 

e.           Survival.   The
obligations of this Section shall extend five (5) years after the expiration or termination of this Agreement, unless such obligations
are terminated earlier pursuant to Section 12.c. above.

 

13.       DATA
AND PUBLICATIONS.

 

The parties
shall jointly own and shall be free to reproduce, publish, and use for any lawful purpose, any data produced by the Research Projects,
subject to the publication requirements set forth in this Section 13. Each party will be free to publish the results of any and
all Research Projects under this Agreement after providing a copy of each proposed publication to the other party at least thirty
(30) days prior to the submission for publication for the other party to review the publication alld provide any comments. If a
party reasonably believes that a disclosure of patentable material is contained in the proposed publication, the parties will work
together to protect to the extent reasonably practicable any potentially patentable subject matter prior to such publication in
a manner consistent with Section 15 below. The parties shall delay such publication to the extent reasonably necessary to protect
such potentially patentable subject matter, such delay not to exceed thirty (30) days in the case of subject matter the patent
prosecution of which is not under DEI's control hereunder. Further, each party shall have the right to redact from any publication
its Confidential Information to the extent the publishing party has all obligation to keep it confidential pursuant to Section
12 above. Any publication resulting from work performed under this Agreement shall acknowledge the contributions of DEI and the
support of the NIH or other grant awarding agency (if applicable) and SSMP. For the avoidal1ce of doubt, any and all publications
related to the Research Products shall be subject to review and approval under this paragraph.

 

14.         USE
OF NAMES.

 

The parties
agree that neither party will use the name, trademark, or other proprietary designation of the other party, or any abbreviation
thereof, or the nan1e of the persom1el of the other party (it being acknowledged that the PIs are DEI Personnel as of the Effective
Date) in any news release, publicity release, advertisement, or other public disclosure in any manner expressing or implying any
endorsement by, or affiliation with, the other party or its personnel without the prior written approval of the other party. This
Section 14 shall not be construed to prohibit: (a) either party from publicly disclosing the parties' relationship hereunder as
reasonably necessary for obtaining patent or other IP Rights (as defined below) or regulatory or other governmental approvals in
any country; (b) DEI from disclosing that SSMP or any applicable grant is the source of funding for any Research Projects to the
extent reasonably necessary for DEI to comply with any reporting or compliance policies; or (c) either party from making any other
disclosure to the extent required by any applicable statute, regulation, order, rule, or other law.

 

    	9

    	 

    

 

15.         INTELLECTUAL
PROPERTY.

 

a.           DEI
IP.

 

(1)    As
between the parties, DEI shall exclusively own all right, title, and interest throughout the world in and to the DEI IP (as
defined herein). As used herein, "DEI IP" means: (i) any inventions
(including without limitation any "subject invention" as that term is defined in 37 C.F.R. 401.14), discoveries,
biological material, works of authorship, trade secrets, know- how, trademarks, and other technology and innovations
(collectively, "Innovations") relating to the Research Products, which
Im1ovations are Developed (where, to "Develop" means to conceive,
reduce to practice, write, create, or otherwise develop) during the period commencing on the Effective Date of this Agreement
and ending on the Termination Date of this Agreement (as defined in Section 21 below) solely by DEI Personnel who are
identified on a DEI invoice as having worked on a Research Project, who are identified in Section 2 of this Agreement, or who
have obtained Confidential Information of SSMP concerning the Research Products, the Pre- existing SSMP IP, other DEI
IP, and/or the Joint IP, whether Developed by DEI alone or jointly with third parties, and any resulting patent, copyright,
trademark, mask work, industrial design, or other intellectual property or proprietary rights ("IP
Rights") associated therewith; and (ii) any Innovations Developed prior to the Effective Date of this
Agreement solely by DEI Personnel and any resulting IP Rights associated therewith, solely to the extent such Innovations and
IP Rights constitute "DEI IP" as defined in the Prior Agreement (the "Prior
DEI IP").

 

(2)     DEI
shall promptly report the Development of any DEI IP or any other Im1ovations relating to the Research Products Developed by the
DEI Personnel described above to SSMP in writing during the term of this Agreement and for one hundred eighty (180) days (the "Follow-On
Period") following the Termination Date. DEI IP licensed in 15g. shall include inventions made during the Follow-On Period
directly resulting from SSMP Confidential Information or SSMP funded research. DEI shall have the burden of proof to demonstrate
that inventions Developed during the Follow-On Period are not DEI IP. For the avoidance of doubt, except for the Prior IP, the
DEI IP shall not include Innovations developed by DEI Personnel who have not been identified on a DEI invoice or SOW as having
worked on a Research Project, who are identified in Section 2 of this Agreement, or who have not obtained any Confidential Information
of SSMP concerning the Research Products, the Pre-existing SSMP IP, and/or the Joint IP, which Innovations the parties acknowledge
are not governed by this Agreement or the Prior Agreement.

 

(3)
    If DEI jointly Develops (or reasonably anticipates jointly Developing) any DEI IP together with one or
more third parties (including without limitation Premitec, Inc.), then DEI will use commercially reasonable efforts to agree
with such third parties that such DEI IP will be jointly owned by all contributing parties on terms consistent with this
Section 15, including but not limited to, the license granted to SSMP in Section 15.g. If, despite such conm1ercially
reasonable efforts, DEI is unable to agree with any such third party on terms consistent with this Section 15, then this
Section 15 (including but not limited to the license granted to SSMP in Section 15.g.) shall apply only to the portion of
such DEI IP developed by DEI Personnel and therefore, actually owned or controlled by DEI and only to the extent of such
ownership or control, provided however that DEI may not, without SSMP's prior written consent, assign or exclusively license
its portion of any such DEI IP for commercial purposes to any third party who does not agree to be bound by the license
granted to SSMP in Section 15.g. below with respect to such DEI IP.

 

    	10

    	 

    

 

(4)
   The parties hereby acknowledge that DEI has jointly Developed with Johns Hopkins University ("JHU"), and
jointly owns with JHU, certain Im1ovations relating to the Research Products and described in U.S. Patent Application No.
11/540,899, filed September 29, 2006 and entitled "Microelectrode System for Neuro-Stimulation and Neuro-sensing and
Microchip Packaging." DEI has not obtained JHU's agreement to terms consistent with this Section 15.
Accordingly, this Section 15 shall apply only to DEI's portion of such Innovations and the IP Rights associated
therewith.

 

b.  Joint
IP.

 

(1)    As
between the parties, all Joint IP (as defined herein) shall be owned jointly by DEI and SSMP subject to the terms hereof The parties
shall not use, license or otherwise exploit any Joint IP, unrelated to the Research Products, without first giving notice to the
other and negotiating in good faith to exploit such IP in a mutually advantageous manner. As used herein, "Joint
IP" means: (i) Innovations Developed during the period commencing on the Effective Date of this Agreement and
ending on the Termination Date of this Agreement jointly by SSMP personnel and DEI Personnel who are identified on a DEI invoice
as having worked on a Research Project, who are identified in Section 2 of this Agreement, or who have obtained Confidential Information
of SSMP concerning the Research Products, the Pre-existing SSMP IP, the DEI IP, and/or the Joint IP and all resulting IP Rights
associated therewith; and (ii) any Innovations Developed prior to the Effective Date of this Agreement jointly by SSMP personnel
and DEI Persom1el, and any resulting IP Rights associated therewith, solely to the extent such Innovations and IP Rights constitute
"Joint IP" as defined in the Prior Agreement (the "Prior Joint IP").

 

(2)     If
SSMP and DEI jointly Develop (or reasonably anticipate jointly Developing) any such Joint IP together with one or more third parties
(including without limitation Premitec, Inc.), then SSMP and DEI will work together, using commercially reasonable efforts, to
agree with each such third party that such Joint IP will be jointly owned by all contributing parties on terms consistent with
this Section 15, including but not limited to, the license granted to SSMP in Section 15.g. If, despite such commercially reasonable
efforts, the parties are unable to agree with any such third party on terms consistent with this Section 15, then this Section
15 (including but not limited to the license granted to SSMP in Section 15.g.) shall apply only to the portion of such Joint IP
developed by DEI Personnel and SSMP, and, therefore, owned or controlled by DEI and SSMP, and only to the extent of such ownership
or control.

 

    	11

    	 

    

 

(3)     In
the case of any such third party who is a Grant Participant, SSMP shall use reasonable commercial efforts to enter into a written
agreement with each such Grant Participant consistent with the terms of this Section 15. Such agreement also shall provide that,
in the event DEI and such Grant Participant jointly Develop any Innovations in the course of the Project without contribution from
SSMP, DEI and such Grant Participant shall own such Innovations and associated IP Rights on terms consistent with the terms of
this Section 15. If, despite such commercially reasonable efforts, SSMP is unable to enter into an agreement consistent with the
terms of Section 15, then this Section 15 (including but not limited to the license granted to SSMP in Section 15.g. below) shall
apply only to that portion of any such Innovations and associated IP Rights that is actually owned and controlled by DEI under
such agreement and only to the extent of such ownership and control. SSMP shall furnish to DEI promptly upon request the relevant
excerpts from any such consortium agreement so that DEI may confirm SSMP's compliance with this Section 15 except to the extent
SSMP is unable to obtain permission from such Grant Participant to do so after using commercially reasonable efforts to obtain
it.

 

c.  Protection.

 

(1)    DEI
agrees to cause patent applications to be filed and prosecuted, and patents maintained, in its name, and at SSMP's sole expense,
on any DEI IP that, in DEI's reasonable judgment, is patentable. DEI shall use patent counsel reasonably acceptable to SSMP for
such purposes. DEI shall promptly notify SSMP of its intent to file a patent application on any such DEI IP and shall provide SSMP
a copy of any such patent application. If, after notification of DEI's intent to file a patent application on DEI IP, SSMP declines
to support said filing, or if SSMP declines to support any prosecution or maintenance costs associated with any such application
or patent issued thereon, DEI may file, prosecute, or maintain (as applicable) such patent application or patent (as applicable)
at its own expense and SSMP shall have no further license or other rights in such patent application or patent or in the DEI IP
covered by such patent application or patent. If rights in any DEI IP reasonably may be jeopardized by any anticipated failure
or delay by DEI in prosecuting any patent applications it has filed, then SSMP may instruct DEI to correct such failure or delay,
or, if DEI is unable or unwilling to do so, DEI will give SSMP the right to instruct DEI's prosecution counsel to do so. The parties
shall cooperate in determining whether and how DEI will protect any non-patentable DEI IP (e.g., copyrights, trademarks), provided
that all such protection shall be at SSMP's sole expense and that if SSMP declines to support any particular intellectual property
protection strategy proposed by DEI, DEI may pursue such strategy at its own expense and SSMP shall have no license or other tights
in any DEI IP covered by such strategy. DEI shall keep SSMP reasonably informed of any developments relating to the filing, prosecution,
or maintenance of any patent applications, patents, or other forms of protection of IP Rights in any DEI IP to which SSMP has any
rights hereunder. For the avoidance of doubt, this paragraph shall not apply to any DEI IP or portion thereof not developed by
DEI Personnel and, therefore, is not owned and controlled by DEI as provided in Section 15.a. above and is subject to the rights
of any third parties owning and controlling such DEI IP or portion thereof as contemplated therein.

 

    	12

    	 

    

 

(2)    SSMP
shall keep DEI reasonably informed of any developments relating to the filing, prosecution, or maintenance of any patent applications,
patents, or other forms of protection of IP Rights in any Joint IP or any other Innovations relating to any Research Products,
whether such Innovations are Developed by SSMP alone or jointly with third parties. Such information shall be provided to DEI when
both SSMP and DEI reasonably believe that DEI Personnel may be co-inventors, including, but not limited to, surgical techniques.
SSMP agrees to cause patent applications to be filed and prosecuted, and any patents maintained, in both parties' names, and at
SSMP's sole expense, on any patentable Joint IP. SSMP shall use patent counsel reasonably acceptable to DEI for such purposes.
SSMP shall promptly notify DEI of its intent to file a patent application on any Joint IP and shall provide DEI a copy of any such
patent application, if possible, at least thirty (30) days before such application is filed for DEI's review and comment. If SSMP
declines to file or prosecute a patent application, or to maintain any patent issued thereon, for any Joint IP, DEI may file, prosecute,
or maintain (as applicable) at its own expense, and SSMP shall have only a non-exclusive license in, such patent application or
patent (as applicable) or the Joint IP covered by such patent application or patent. All of SSMP's ownership rights in such Joint
IP shall be assigned to DEI automatically upon such decline. The parties shall cooperate in determining whether and how SSMP will
protect any non-patentable Joint IP (e.g., copyrights, trademarks), provided that all such protection shall be at SSMP's sole expense
and that if SSMP declines to suppm1 any particular intellectual property protection strategy proposed by DEI, DEI may pursue such
strategy at its own expense and SSMP shall have only a non-exclusive license in any DEI IP covered by such strategy. All of SSMP's
ownership rights in such Joint IP shall be assigned to DEI automatically upon such decline.

 

d.  Enforcement.

 

Each party
will notify the other promptly in writing when any infringement by another is uncovered or suspected regarding any DEI IP or Joint
IP in which SSMP has any rights hereunder. As long as the license granted in Section 15.g. below remains exclusive, SSMP shall
have the sole right to enforce any patent included within the DEI IP or Joint IP covered by such license against any alleged infringement
thereof and shall at all times keep DEI informed as to the status thereof. If SSMP chooses to enforce such patents, it may, in
its reasonable judgment and at its own expense, take steps to control, settle, and defend such suits in a manner consistent with
the terms and provisions hereof (and that does not jeopardize the validity of the patent at issue without the written consent of
DEI) and recover for the parties' account any damages, awards, or settlements resulting therefrom. The right to sue for infringement
shall not be used by SSMP in an arbitrary and capricious manner, and DEI may not be named a party in any litigation to enforce
or defend any DEI IP or Joint IP or as a party to any settlement without its prior written consent. DEI shall reasonably cooperate
in any such litigation, and may retain outside counsel in connection therewith, at SSMP's sole expense. Any royalties, license
fees, or other amounts recovered by SSMP shall be deemed to be Net Sales hereunder, and SSMP shall pay royalties to DEI on such
Net Sales as provided in this Agreement. Notwithstanding anything to the contrary herein, if SSMP does not analyze and notify any
alleged infringers within one year of notification of any infringement, or if SSMP does not file suit against any alleged infringers
or fails to resolve any infringement by license or otherwise within two years of any such notification, DEI may enforce such patents
and be entitled to any recovery. SSMP shall reasonably cooperate in any such enforcement effort. For the avoidance of doubt, this
paragraph shall not apply to any DEI IP, Joint IP, or portion thereof not developed by DEI Personnel or SSMP and, therefore, is
not owned and controlled by DEI and/or SSMP as provided in Sections

15.a. and 15.b. above and is
subject to the rights of any third parties owning and controlling such

DEI IP, Joint IP, or portion
thereof as contemplated therein.

 

    	13

    	 

    

 

e.         Pre-existing
SSMP Intellectual Property. Each party retains all IP Rights that it may have as of the Effective Date, subject to the license
granted to DEI in Section 15.f. below, and the licenses granted to SSMP under 15.g. below. Without limiting the generality of the
foregoing, the parties acknowledge that SSMP is the exclusive licensee of U.S. Patent 5,109,844, entitled Retinal Microstimulation,
U.S. Patent 5,935,155, entitled Visual Prosthesis and Method of Using Same, and U.S. Patent 5,944,747 entitled A
Method for Preferential Outer Retinal Stimulation (collectively, the "Pre-existing SSMP
IP"). SSMP believes that rights under the Pre-existing SSMP IP are necessary to complete one or more of the Research
Projects.

 

f           License
to DEI. Subject to the terms of this Agreement, SSMP grants to DEI and its Affiliates, a fully paid-up, royalty-free, worldwide,
non-exclusive, non-revocable license, without the right to sublicense without SSMP's prior written consent, under the Pre-existing
SSMP IP and Joint IP to conduct the Research Projects and to make, have made, use and provide materials for DEI's and its Affiliates'
nonprofit clinical and internal research and educational purposes, but not to sell, distribute, or otherwise make any such materials
commercially available. The license grant under Pre-existing SSMP IP is subject to rights retained by the United States Government
in accordance with P.L. 96-517, as amended by P.L. 98-620, and as set forth in 37 C.F.R. Part 401.

 

g.         License
to SSMP. Subject to the terms of this Agreement, DEI grants to SSMP a worldwide, exclusive, royalty-bearing license, with right
to sublicense, under the DEI IP and the Joint IP to make, have made, use, lease, import, and sell any Licensed Products. This license
(and any associated royalty obligations set forth herein) shall expire upon the termination of the last of the IP Rights in the
DEI IP and the Joint IP if not earlier terminated in accordance with this Agreement. This license grant is subject to a retained
right in DEI to make, have made, use and provide materials for DEI's and its Affiliates' nonprofit clinical and internal research
and educational purposes, but not to sell, distribute or otherwise make any such materials commercially available. This license
grant is further subject to a retained right of the United States Government in accordal1ce with P.L. 96-517, as amended by P.L.
98-620, and as set forth in 37 C.F.R. Part 401 and any other rights retained by the government. SSMP shall not use, license, or
otherwise exploit any DEI IP other than pursuant to this Section 15.g. For the avoidance of doubt, the license granted in this
Section 15.g. shall not apply to any DEI IP, Joint IP, or portion thereof not Developed by DEI Personnel or SSMP and, therefore,
is not owned and controlled by DEI and/or SSMP as provided in Sections 15.a. and 15.b. above and is subject to the rights of any
third parties owning and controlling any such DEI IP, Joint IP, or portion thereof as contemplated therein.

 

h.           Cooperation.
The parties agree to cooperate reasonably with each other and to execute all documents reasonably necessary to vest in each party
the ownership, prosecution, enforcement, and other rights in and to the DEI IP and Joint IP set forth in this Section 15 and to
record and otherwise perfect such rights. Except as otherwise disclosed or provided in this Agreement, neither party believes it
has entered into any agreement with any third party in conflict with this Section 15, and each party agrees that it will not enter
into any agreement that such party believes to be in conflict with this Section 15 without the consent of the other party.

 

i.            Prior
Agreement. The parties acknowledge and agree that, except as expressly set forth in this Agreement, this Agreement (and not
the Prior Agreement) shall govern the parties rights and obligations with respect to the Prior DEI IP and the Prior Joint IP in
all respects and the Prior Agreement shall be of no further force or effect with respect to such matters.

 

    	14

    	 

    

 

16.       COMMERCIALIZATION
EFFORTS.

 

a.           Best
Efforts. SSMP warrants that it will use its best efforts to develop, make, market, sell, obtain all applicable legal and regulatory
approvals, and otherwise commercialize (collectively, "Commercialize") the Licensed Products and that the Commercialization
of such Licensed Products shall be in compliance with all applicable laws and regulations, including but not limited to all product
liability, medical device, export, and IP Rights-related laws. Upon the request of DEI, but not more frequently than annually,
SSMP shall submit to DEI a report detailing its research, regulatory approval, marketing, and product development objectives in
the coming year, as well as SSMP's progress on such activities in the prior year. Such reports shall identify specific future milestones
(e.g., regulatory approvals and product development goals) and information demonstrating that SSMP is providing sufficient financial
and manpower resources to evidence its use of best efforts. In the event that SSMP fails to use its best efforts to Commercialize
any Licensed Products in any jurisdiction, or in spite of its best efforts fails to Commercialize any Licensed Products within
such jurisdiction within a commercially reasonable time, then the license set forth in Section 15.g. to SSMP from DEI shall become
non-exclusive in such jurisdiction upon notice from DEI.

 

b.           Marking.
SSMP agrees to ensure that all Licensed Products and all product literature, advertising, labels, packages, and other materials
for all Licensed Products will be marked with the number of the applicable patent(s) or other IP Rights included within the DEI
IP and Joint IP to which SSMP has any rights hereunder in accordance with each jurisdiction's laws regarding such IP Rights. SSMP
will provide DEI with copies of any labels for such Licensed Products and of any other such materials promptly upon request.

 

c.           Manufacture.
SSMP agrees that any and all Licensed Products sold, licensed, leased, or used within the United States of America shall be manufactured
substantially in the United States of America, unless a written waiver is obtained in advance from the relevant United States federal
agency.

 

d.           Export.
SSMP acknowledges that DEI is subject to United States statutes, regulations, and other laws controlling the export of technical
data, computer software, laboratory prototypes, and other technology, and that its obligations hereunder are contingent on compliance
with all such laws. SSMP shall, at its own expense, obtain and or pay all import and export licenses and permits, customs charges
and duty fees, if any, and shall take all other actions, if any, required to accomplish the export and import of any information
provided by DEI hereunder or of any Licensed Products. To the extent required by applicable law, SSMP shall not knowingly disclose
any of DEI's Confidential Information or transfer any Licensed Products or other materials: (i) to (or to a national or resident
of) Cuba, Iran, Sudan, Syria, or any other country that the U.S. has embargoed, so long as an embargo exists; (ii) to anyone on
the Bureau of Industry and Security's denied persons or entities lists, the U.S. Treasury Departments' specially designated nationals
list, the U.S. State Department's debarred list, or any similar list of any persons, entities, or countries; or (iii) in any other
manner that would violate any applicable statutes, orders, regulations, rules, treaties, or other laws.

 

    	15

    	 

    

 

17.       USC

 

SSMP acknowledges
that: (i) the PIs and other DEI Personnel also may be employees of USC; (ii) USC shall be deemed to be an Affiliate of DEI for
all purposes of this Agreement; and (iii) USC may have an interest in any DEI IP or Joint IP in which DEI has any interest, and,
under some circumstances, USC may have the sole interest in any DEI IP or Joint IP developed by certain DEI Personnel, in each
case in accordance with agreements and arrangements between DEI and USC, which have not been disclosed to SSMP. This Agreement
does not affect any such agreements or arrangements. DEI hereby warrants that it has obtained approvals from USC sufficient to
grant the license herein (including with respect to the Prior DEI IP and the Prior Joint IP and including approval to grant the
license in Section 15.g. above).

 

18.       INDEMNITY;
INSURANCE.

 

a.           Indemnity. SSMP
shall indemnify, defend, and hold harmless DEI and its Affiliates and the respective trustees, officers, directors,
employees, and agents of each, from and against any and all third party claims, demands, causes of action, actions, suits, or
proceedings, and from and against any and all losses, damages, judgments, settlements, liabilities, costs, and expenses,
including without limitation legal expenses and attorneys' and experts' fees and costs, arising out of or relating to: (i)
performance of the Research Projects; (ii) any negligence or intentional misconduct of SSMP or any breach of this Agreement
by SSMP; (iii) any materials or information provided by SSMP, including, without limitation, any claim that any material or
information provided by SSMP infringes upon or misappropriates any IP Rights of a third party;
(iv) the death of, or injury to, any person or persons, or any damage to
property, resulting from, or arising out of, the manufacture, use, handling, testing, sale, disposal, or other exploitation
of any products created by any SSMP Parties; or (v) any efforts by any SSMP Parties to Commercialize or otherwise exploit any
Licensed Product, DEI IP, Joint IP, or other technology or IP Rights created or licensed hereunder.

 

b.           Insurance.
SSMP shall obtain and maintain, at its own expense, standard product liability insurance coverage, comprehensive general liability
coverage and other insurance that is commonly utilized in the industry for comparable transactions naming DEI and the other indemnities
set forth in subsection (a) above as additional named insured. Such policies shall: (i) be maintained with a carrier having a rating
from AM Best of at least "A"; and (ii) provide protection against any claims, demands and causes of action set forth
in subsection (a) above and claims, demands, and causes of action arising out of any manufacture, sale, export, license, lease
or other use or Commercialization of any Licensed Product, and any product or service based on or related to any IP Rights or technology
created hereunder. The amount of such coverage shall be a minimum of $1,000,000, or such greater amount as may be commercially
reasonable under the circumstances, with no deductible amount, for each single occurrence for bodily injury or property damage.
The policies shall provide for notice to DEI from the insurer by registered or certified mail in the event of any modification
or termination of insurance and SSMP may only tem1inate or modify such policies if it replaces such policies with policies equally
protective of DEI and the indemnities in subsection (a) above without interruption of time.         SSMP
shall furnish DEI certificates from its product liability and other insurance carriers evidencing insurance coverage in favor of
DEI and the indemnities in subsection (a) above, and in no event shall SSMP distribute, perform or otherwise Commercialize any
Licensed Product, or any product or service based on or related to any IP Rights or technology developed
hereunder before receipt by DEI of current evidence of insurance. The provisions of this Section shall survive expiration or termination
of this Agreement as long as there is any manufacture, sale, export, use, or other Commercialization of any Licensed Product, or
any product or service based on or relating to any IP Rights or technology created hereunder.

 

    	16

    	 

    

 

19.       WARRANTY
DISCLAIMER.

 

EXCEPT AS
EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY SPECIFICALLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES,
EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, TITLE, AND NON-INFRINGEMENT, AND IMPLIED WARRANTIES ARISING FROM COURSE OF DEALING OR PERFORMANCE ARISING OUT OF OR RELATED
TO THIS AGREEMENT, AS WELL AS ANY EQUITABLE INDEMNITIES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, DEI SPECIFICALLY DISCLAIMS
ANY WARRANTIES RELATING TO THE DEI IP, THE JOINT IP, OR ANY WORK PERFORMED HEREUNDER.

 

20.          LIMITATION
OF LIABILITY.

 

EXCEPT FOR
THE INDEMNITY OBLIGATIONS SET FORTH IN SECTION 18 ABOVE OR IN THE CASE OF ANY WILLFUL MISCONDUCT OR FRAUD, IN NO EVENT SHALL EITHER
PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH
OF CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, AND WHETHER OR NOT THAT PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGE. EXCEPT FOR THE INDEMNITY OBLIGATIONS SET FORTH IN SECTION 18 ABOVE OR IN THE CASE OF ANY WILLFUL MISCONDUCT OR FRAUD, IN
NO EVENT SHALL THE AGGREGATE LIABILITY OF EITHER PARTY ARISING HEREUNDER, WITH RESPECT TO OR IN CONNECTION WITH THIS AGREEMENT
EXCEED THE TOTAL MONIES PAID OR PAYABLE BY SSMP TO DEI UNDER THIS AGREEMENT DURING THE TWELVE (12) MONTH PERIOD IMMEDIATELY PRECEDING
THE DATE ON WHICH SUCH LIABILITY ARISES.

 

21.       TERM
AND TERMINATION.

 

a.           Term.
Each SOW shall commence on the effective date stated therein and expire upon the termination of the Period of Performance set forth
therein, unless earlier terminated in accordance herewith. This Agreement shall commence on the Effective Date and shall expire
upon the expiration or termination of all SOWs hereunder (the "Termination Date"), provided
however that the parties may extend this Agreement by mutual written agreement to facilitate the formation of additional then-contemplated
SOWs should they desire to do so.

 

b.           Convenience.
Either party may terminate any SOW (and the Research Project described therein) upon thirty (30) days prior written notice to the
other party for any reason or no reason.

 

    	17

    	 

    

 

c.           Breach.
Either party may terminate any affected SOW (and the Research Project described therein) or this Agreement upon written notice
to the other party if the latter party breaches any material term, obligation, representation, or warranty in tills Agreement or
the applicable SOW and fails to cure such breach within thirty (30) days after receiving notice thereof, provided that if DEI fails
to cure such breach, such failure is not the direct or indirect result of any failure by SSMP to provide DEI with any information,
materials, or assistance contemplated by tills Agreement or the applicable SOW or to reimburse DEI in accordance with tills Agreement
and the applicable SOW.

 

d.           PI.
Either party may immediately terminate any SOW (and the Research Project described therein) upon written notice if no specified
person is able to continue to serve as PI for the affected Research Project(s) specified in the applicable SOW(s) and the parties
are unable to agree upon an available successor PI within ten (10) days, as referenced in Section 2 above.

 

e.           Costs.
DEI may immediately terminate any SOW (and the Research Project described therein) upon written notice if SSMP does not authorize
additional reimbursement of DEI's costs for the affected Research Project(s) specified in the applicable SOW(s) within ten

(10) days of DEI's request, as referenced in Section
5 above.

 

f.            Assignment;
Insolvency. Either party may immediately terminate any SOW or this Agreement upon written notice if the other party has: (i)
attempted to assign this Agreement in violation of Section 23 below; or (ii) availed itself of, or been subjected by a third party
to, a proceeding in bankruptcy, an assignment for the benefit of creditors, the appointment of a receiver or other proceeding involving
insolvency or protection from creditors or similar proceedings under applicable law.

 

g.           Effects
of Termination on Services. Upon expiration or termination of any SOW or the Agreement for any reason, SSMP will pay for costs
incurred through the date of expiration or termination, and DEI will furnish all necessary reports of services performed for each
affected Research Project, whether such services are completed or in progress, through the date of expiration or termination, provided
that DEI has received full reimbursement from SSMP of the costs associated with such services. Said costs may include, without
limitation, all non- cancelable obligations, as well as all other costs to the extent qualifying as allowable termination costs
pursuant to OMB Circulars A-110 or A-122, to the extent such OMB Circulars are applicable hereto. All previously invoiced amounts
shall immediately become due and payable.

 

h.           Effects
of Termination on Licensed Rights. In the event of termination of this Agreement by DEI pursuant to Sections 2l.c. or 2l.f.
(but not an expiration or termination of tills Agreement pursuant to Section 2l.a., 2l.b, 2l.d., or 2l.e. above), all rights licensed
to SSMP pursuant to Section 15.g. above shall immediately terminate. Within twenty (20) days after such termination, SSMP shall
provide DEI with a written inventory of all Licensed Products that are either completed or works in process in its possession as
of the date of termination (the "Inventory"). SSMP shall have the right to
complete and sell all Licensed Products specified in the Inventory subject to all of SSMP's royalty payment and other obligations
set forth herein, provided that the amounts set forth in the Inventory are reasonable and consistent with prevailing industry standards
for products of the same type as the Licensed Products. DEI shall have the right to take a physical inventory of the Licensed Products
that are either completed or works in process in SSMP's possession and to access SSMP's databases
sufficient to confirm the Inventory. Refusal by SSMP to permit a physical inventory or access to the databases by DEI shall forfeit
SSMP's right to sell or otherwise dispose of any Licensed Products after termination.

 

    	18

    	 

    

 

i.            Return
of Materials. Upon expiration or termination of this Agreement for any reason, or upon request by either party, each party
(or the non-requesting party, as applicable) shall deliver to the other party or destroy, at the option of the delivering or destroying
party all tangible copies of, or tangible materials containing or embodying any, Confidential Information of the other party then
subject to the obligations in Section 12 above and in possession or control of such party and shall erase all electronic files
in its possession or under its control containing any such Confidential Information; provided, however, that the delivering or
destroying party may retain a copy of such Confidential Information in its legal files to maintain a legal record of the Confidential
Information provided under this Agreement and to ensure compliance with the obligations of this Agreement, and provided further
that copies of files containing any such Confidential Information may remain on such party's standard computer back-up devices
(which copies such party agrees not to access thereafter except as permitted herein).

 

j.            Survival.
All definitions, and the parties' rights and obligations set forth in Sections 7, 8, 9 through 15 (except as set forth in Section
21.h.), and 18 through 28, shall survive the expiration or earlier termination of this Agreement for any reason, in each case to
the extent consistent with the terms thereof.

 

k.          Remedies.
Expiration or termination of an SOW or this Agreement shall not terminate either party's rights or obligations with respect to
matters arising out of events occurring prior to the effective date of such expiration or termination. Each party's rights of termination
under this Section 21 are in addition to, rather than in lieu of, any other rights of, or remedies available to, such party.

 

22.       NOTICES.

 

Any notices
required or permitted to be given under this Agreement shall be in writing, delivered by hand, prepaid certified or registered
mail (rettm1 receipt requested), nationally recognized overnight courier that provides confirmation of delivery (such as Federal
Express), or facsimile, directed to the parties as follows:

 

For DEI:

 

Marissa Goldberg, V.P., Administration

Doheny Eye Institute

1450 San Pablo Street #3025

Los Angeles, CA 90033

Telephone: (323) 442-7123

Facsimile: (323) 442-7127

 

    	19

    	 

    

 

For SECOND SIGHT:

 

Robert J.
Greenberg, M.D., Ph.D. President

Second Sight Medical Products, Inc.

12744 San Fernando Road, Bldg 3

Sylmar, California 91342

Telephone: (818) 833-5050

Facsimile: (818) 833-5067

 

All notices,
statements, and payments required or permitted under this Agreement shall be deemed to be given when delivered in person, five
(5) business days after being sent by prepaid are sent by certified or registered mail, on the first business day on or after the
date on which delivery is confirmed by courier, or on the first business day on or after the date on which facsimile delivery is
confirmed by the sending machine. Either party may change its contact information for notices by giving notice to the other party
as provided herein.

 

23.       ASSIGNMENT.

 

Neither
party may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other party;
any such consent shall not be unreasonably withheld or delayed. Notwithstanding the foregoing, either party may assign this Agreement
to the successor to all or substantially all of the business or assets to which this Agreement relates without the consent of the
other party, provided that prompt notice of such assignment is given to the other party. Any assignment in violation of this provision
shall be null and void. This Agreement shall be binding on and inure to the benefit of all permitted successors and assigns.

 

24.       DISPUTE
RESOLUTION.

 

a.           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California without regard
to any conflicts of laws principles.

 

b.           Arbitration.
Except as set forth in Section 24.c. below, all disputes arising under or relating to this Agreement shall be submitted by
either party to private m1d confidential arbitration by a single neutral arbitrator. Subject to the terms of this Section 24, the
comprehensive Commercial Arbitration Rules of the American Arbitration Association (AAA) shall govern the arbitration proceedings
m1d the provisions of California Code of Civil Procedure Section 1283.05 will apply. The arbitrator shall be appointed by agreement
of the parties hereto or, if no agreement can be reached, by the AAA pursuant to its applicable rules from a list of three arbitrators
submitted by each party. The arbitration shall take place in Los Angeles, California. The arbitrator shall have no authority to
vary from or ignore the terms of this Agreement and shall be bound by the controlling law as provided above. The decision of the
arbitrator shall be final and binding on both parties and may be entered as final judgment in any court having competent jurisdiction.
The costs of the arbitrator and of the fees of the AAA shall be divided equally among the parties; otherwise, the prevailing party
shall be entitled to an award of its fees and costs, including without limitation its attorneys' and experts' fees and costs. This
arbitration procedure is intended to be the sole and exclusive method of resolving any claim arising out of or relating to this
Agreement, except as noted above.

 

    	20

    	 

    

 

c.           Courts.
Either party may seek provisional relief, including without limitation restraining orders, injunctions, and attachments, and may
enter judgment on any arbitration award, in any court of competent jurisdiction. For such purposes, the parties hereby submit themselves
to the non-exclusive jurisdiction of the state and federal courts located in
Los Angeles, California and waive any objection thereto on the basis of personal jurisdiction, venue, and convenience of
the forum, or on any other basis.

 

25.       ENTIRE
AGREEMENT.

 

Unless otherwise
specified, this Agreement, including all of the SOWs attached hereto, embodies the entire understanding between DEI and SSMP with
respect to the Research Projects, the DEI IP, and the Joint IP, and any prior or contemporaneous representations or agreements,
whether in oral, written, electronic, or other form (including without limitation the Prior Agreement), are hereby superseded.
This Agreement shall not be deemed or construed to be modified, amended, or otherwise varied, in whole or in party, including without
limitation through changes in any SOW, except by written amendment signed by authorized representatives of both parties or as otherwise
expressly set forth herein. The body of this Agreement and any SOW attached hereto shall be construed to the extent possible so
as to be consistent with one another; in the event of any conflict between any provision in the body of this Agreement and any
provision in any SOW, the provision in the SOW shall control.

 

26.         RELATIONSHIP.

 

The parties
to this Agreement are independent contractors and nothing herein shall be construed as creating an employment, agency, franchise,
joint venture, or partnership relationship between the parties. Except as set forth herein, neither party shall have any right,
power, or authority to enter into any agreement for or on behalf of, or incur any obligation or liability, or to otherwise bind,
the other party.

 

27.         WAIVER;
SEVERABILITY.

 

In the event
that any provision of this Agreement is in conflict with any statute, regulation, order, rule, or other law or is otherwise unenforceable
under applicable law, such provision shall be deemed stricken from this Agreement and the remaining provisions of this Agreement
shall continue in full force and effect, but only if consistent with the economic intent of the parties as evidenced by this Agreement
as a whole. No failure by either party to take action or assert any right hereunder shall be deemed to be a waiver of such right
in the event of the continuation or repetition of the circumstances giving rise to such right or a waiver of any other right.

 

    	21

    	 

    

 

28.       COUNTERPARTS.

 

This Agreement
and each SOW may be executed in original or facsimile counterparts, each of which shall be deemed an original and all of which,
taken together, shall constitute one and the same instrument.

 

IN WITNESS
WHEREOF, the parties have caused this Agreement to be executed by duly authorized persons as of the Effective Date.

 

	DOHENY EYE INSTITUTE	 	SECOND SIGHT MEDICAL PRODUCTS, INC.
	 	 	 	 	 
	By:	 	 	By:	 
	Name:	Marisa Goldberg	 	Name:	Robert J. Greenberg, M.D., Ph.D
	Title:	V.P., Administration	 	Title:	President

 

    	22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]